TLDR Morgan Stanley reported Q4 earnings of $2.68 per share, beating analyst estimates of $2.44, with revenue of $17.89 billion exceeding expectations of $17.77TLDR Morgan Stanley reported Q4 earnings of $2.68 per share, beating analyst estimates of $2.44, with revenue of $17.89 billion exceeding expectations of $17.77

Morgan Stanley (MS) Stock: Earnings Beat Expectations as Wealth Management Fuels Growth

TLDR

  • Morgan Stanley reported Q4 earnings of $2.68 per share, beating analyst estimates of $2.44, with revenue of $17.89 billion exceeding expectations of $17.77 billion.
  • Wealth management drove results with $8.4 billion in net revenue, up from $7.5 billion a year ago, while total client assets reached $9.3 trillion.
  • Investment banking revenue jumped 47% to $2.41 billion, driven by stronger advisory fees and increased M&A activity across all regions.
  • The bank bought back $1.5 billion in stock during Q4 and $4.6 billion for the full year under its share repurchase program.
  • Morgan Stanley shares gained 38% over the past 12 months but fell nearly 3% this week as other banks reported results.

Morgan Stanley posted fourth-quarter earnings that topped Wall Street estimates on Thursday. The results were driven by strong performance in wealth management and investment banking.

The bank reported earnings of $2.68 per share. Analysts had expected $2.44 per share. Revenue came in at $17.89 billion, beating the $17.77 billion estimate.

Net income for the quarter rose to $4.40 billion. That’s up from $3.71 billion in the same period last year. The earnings translated to $2.68 per share compared to $2.22 per share a year ago.


MS Stock Card
Morgan Stanley, MS

Revenue increased to $17.89 billion from $16.22 billion in the prior year. The wealth management division led the charge with $8.4 billion in net revenue. This marked an increase from $7.5 billion a year earlier.

For the full year, wealth management generated a record $31.8 billion in net revenue. Total client assets in the wealth and investment management business climbed to $9.3 trillion. The firm pulled in more than $350 billion in net new assets.

Investment Banking Delivers Strong Results

The investment banking segment showed impressive growth. Net revenue for the division jumped 47% to $2.41 billion from $1.64 billion a year earlier.

The increase came from stronger advisory fees. Completed M&A activity increased across all regions during the quarter.

Morgan Stanley bought back $1.5 billion of its stock during the quarter. For the full year, the bank repurchased $4.6 billion under its share repurchase program.

The firm also filed paperwork for spot Bitcoin and Solana ETFs. This move signals an expansion into crypto products that could boost fee revenue.

Morgan Stanley’s private equity arm took majority control of engineering firm Olsson. The deal shows the bank is expanding its alternative investment offerings.

Stock Performance and Analyst Views

Morgan Stanley shares gained 38% over the past 12 months. However, the stock fell nearly 3% this week as other major banks reported their results.

The stock opened at $180.77 on Thursday. The bank has a market cap of $287.30 billion.

Several analysts have updated their price targets recently. Jefferies Financial Group lifted its target from $186 to $212 with a buy rating. UBS Group raised its target from $156 to $165 with a neutral rating.

Three analysts rate the stock as a strong buy. Eight have given it a buy rating. Eight analysts issued a hold rating. The consensus rating is “Moderate Buy” with an average price target of $181.85.

CEO Edward Pick sold 100,000 shares in late October at an average price of $164.34. The transaction totaled $16.43 million. Following the sale, Pick directly owned 574,986 shares.

Institutional investors own 84.19% of Morgan Stanley stock. Several hedge funds adjusted their positions in the stock during the third quarter.

The bank reported a return on equity of 16.40% and a net margin of 13.85%. The company has a price-to-earnings ratio of 18.54 and a debt-to-equity ratio of 3.27.

The post Morgan Stanley (MS) Stock: Earnings Beat Expectations as Wealth Management Fuels Growth appeared first on Blockonomi.

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$0.36614
$0.36614$0.36614
-5.68%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple!

Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple!

Buterin unveils Ethereum’s strategy to tackle quantum security challenges ahead. Ethereum focuses on simplifying architecture while boosting security for users. Ethereum’s market stability grows as Buterin’s roadmap gains investor confidence. Ethereum founder Vitalik Buterin has unveiled his long-term vision for the blockchain, focusing on making Ethereum quantum-secure while maintaining its simplicity for users. Buterin presented his roadmap at the Japanese Developer Conference, and splits the future of Ethereum into three phases: short-term, mid-term, and long-term. Buterin’s most ambitious goal for Ethereum is to safeguard the blockchain against the threats posed by quantum computing.  The danger of such future developments is that the future may call into question the cryptographic security of most blockchain systems, and Ethereum will be able to remain ahead thanks to more sophisticated mathematical techniques to ensure the safety and integrity of its protocols. Buterin is committed to ensuring that Ethereum evolves in a way that not only meets today’s security challenges but also prepares for the unknowns of tomorrow. Also Read: Ethereum Giant The Ether Machine Takes Major Step Toward Going Public! However, in spite of such high ambitions, Buterin insisted that Ethereum also needed to simplify its architecture. An important aspect of this vision is to remove unnecessary complexity and make Ethereum more accessible and maintainable without losing its strong security capabilities. Security and simplicity form the core of Buterin’s strategy, as they guarantee that the users of Ethereum experience both security and smooth processes. Focus on Speed and Efficiency in the Short-Term In the short term, Buterin aims to enhance Ethereum’s transaction efficiency, a crucial step toward improving scalability and reducing transaction costs. These advantages are attributed to the fact that, within the mid-term, Ethereum is planning to enhance the speed of transactions in layer-2 networks. According to Butterin, this is part of Ethereum’s expansion, particularly because there is still more need to use blockchain technology to date. The other important aspect of Ethereum’s development is the layer-2 solutions. Buterin supports an approach in which the layer-2 networks are dependent on layer-1 to perform some essential tasks like data security, proof, and censorship resistance. This will enable the layer-2 systems of Ethereum to be concerned with verifying and sequencing transactions, which will improve the overall speed and efficiency of the network. Ethereum’s Market Stability Reflects Confidence in Long-Term Strategy Ethereum’s market performance has remained solid, with the cryptocurrency holding steady above $4,000. Currently priced at $4,492.15, Ethereum has experienced a slight 0.93% increase over the last 24 hours, while its trading volume surged by 8.72%, reaching $34.14 billion. These figures point to growing investor confidence in Ethereum’s long-term vision. The crypto community remains optimistic about Ethereum’s future, with many predicting the price could rise to $5,500 by mid-October. Buterin’s clear, forward-thinking strategy continues to build trust in Ethereum as one of the most secure and scalable blockchain platforms in the market. Also Read: Whales Dump 200 Million XRP in Just 2 Weeks – Is XRP’s Price on the Verge of Collapse? The post Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple! appeared first on 36Crypto.
Share
Coinstats2025/09/18 01:22
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26